Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, February 3, 2016
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Tue, February 2, 2016
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Mon, February 1, 2016
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Biren Amin Upgraded (VRTX) to Strong Buy and Held Target at $120 on, Feb 1st, 2016
Biren Amin of Jefferies, Upgraded "Vertex Pharmaceuticals Incorporated" (VRTX) to Strong Buy and Held Target at $120 on, Feb 1st, 2016.
Biren has made no other calls on VRTX in the last 4 months.
There are 3 other peers that have a rating on VRTX. Out of the 3 peers that are also analyzing VRTX, 0 agree with Biren's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Biren
- Paul Matteis of "Stifel" Initiated at Strong Buy and Held Target at $125 on, Tuesday, December 1st, 2015
- Andrew Fein of "HC Wainwright & Co." Upgraded from Hold to Strong Buy and Increased Target to $155 on, Friday, October 30th, 2015
- Matthew Harrison of "Morgan Stanley" Upgraded from Hold to Buy and Increased Target to $148 on, Friday, October 2nd, 2015
